Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:CEO |
Pierluigi Antonelli
|
| gptkbp:countryOfOrigin |
gptkb:Germany
|
| gptkbp:focusArea |
biosimilars
parenteral nutrition transfusion technology IV drugs |
| gptkbp:foundedYear |
1999
|
| gptkbp:headquartersLocation |
gptkb:Bad_Homburg,_Germany
|
| https://www.w3.org/2000/01/rdf-schema#label |
Fresenius Kabi
|
| gptkbp:industry |
healthcare
pharmaceuticals medical devices |
| gptkbp:notableAcquisition |
APP Pharmaceuticals
Akorn's assets Fenwal |
| gptkbp:numberOfEmployees |
over 40,000
|
| gptkbp:operatesIn |
global
|
| gptkbp:parentCompany |
gptkb:Fresenius_SE_&_Co._KGaA
|
| gptkbp:products |
generic drugs
medical devices clinical nutrition infusion therapy |
| gptkbp:stockExchange |
FSE (as part of Fresenius SE & Co. KGaA)
|
| gptkbp:website |
https://www.fresenius-kabi.com/
|
| gptkbp:bfsParent |
gptkb:Gerastart_IV
gptkb:Gerastart_VI gptkb:SCA_Pharmaceuticals gptkb:Fresenius gptkb:Vincasar_PFS |
| gptkbp:bfsLayer |
7
|